Multisite mutation of monomer survivin with enhanced effect on apoptosis regulation of breast cancer cells.

Guoying Dai,Wenyun Zheng,Xingyuan Ma,Ping Wang
DOI: https://doi.org/10.1016/j.biopha.2014.11.015
2014-01-01
Abstract:Survivin is an important protein in regulating both cell apoptosis and proliferation. It has attracted growing attentions in recent years as a promising target for cancer therapy. Previous studies have revealed that monomeric survivin regulated apoptosis in a more significant way than the wild-type survivin that generally contains a large portion of its dimers. In order to investigate the roles of monomeric mutant survivin apoptosis and cell cycle regulation of human cancer cells, we developed and tested three dominant-negative mutants with multisite mutations (MSM) including TAT-survivin(34/101/102), TAT-survivin(34/117/101/102) and TAT-survivin(117/101/102). Results revealed that MSM mutants remained as monomers under ambient conditions, and induced cells (breast cancer Bcap-37 cells) apoptosis even more efficiently, primarily through the caspase-dependent and Bcl-2-related pathways, than non-monomeric mutants. We further identified that the TAT-survivin(34/101/102) and TAT-survivin(117/101/102) MSM significantly inhibited the proliferation of Bcap-37 cells and arrested cells in S and G2/M phases, while TAT-survivin(34/117/101/102) arrested cells in G2/M phase. It appeared to us that TAT-survivin(34/101/102) and TAT-survivin(117/101/102) also inhibited cell proliferation more significantly. These findings suggest that such MSM afford monomeric survivin with promising potentials for cancer therapy.
What problem does this paper attempt to address?